Telos Capital Advisors announces the sale of Vital Art and Science to Genentech, a member of the Roche Group. The assets purchased included patents, the FDA approved medical device app, and related software. The mVT App is designed to detect early vision changes in patients with AMD and Diabetic Eye Disease. We are proud to have worked with the Vital Art and Science team to place this sight saving device with a global pharmaceutical firm with the resources to fully deploy it.
Comentários